Human Services (HHS) was given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS has delegated program responsibility to CDC.

In addition, a memo was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

Purpose: This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community, American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at this DOE site. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters To Be Discussed: Agenda items include: presentations from the National Center for Environmental Health (NCEH) regarding current activities and the National Institute for Occupational Safety and Health and ATSDR will provide updates on the progress of current studies.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Paul G. Renard, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, M/S F–35, Atlanta, Georgia 30341–3724, telephone 770/488–7040, fax 770/488–7044.

Dated: January 26, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–2436 Filed 1–30–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0507]

Mountaire Vitamins, Inc., et al.; Withdrawal of Approval of NADA's

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of eight new animal drug applications (NADA's) as requested by the sponsors. The NADA's provide for use of products that are no longer made or marketed. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the regulations by removing the entries that reflect approval of the NADA's.

EFFECTIVE DATE: February 12, 1998.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1722.

SUPPLEMENTARY INFORMATION: The following sponsors have requested withdrawal of approval of NADA's that provide for use of the animal drug products noted:

NADA No.	Drug name	Sponsor name and address
38–247	Hygromycin B Type A medicated article	Mountaire Feeds, Inc., 124 East Fifth, P.O. Box 5391, North Little Rock, AR 72119, formerly Mountaire Vitamins, Inc., 400 North Poplar St., P.O. Box 9210, North Little Rock, AR 72119
44–013	Tylosin Type A medicated article	do.
65–273	Chloramphenicol capsules, USP	Zenith Goldline Pharmaceuticals, Inc., 140 Legrand Ave., Northvale, NJ 07647, formerly Zenith Laboratories, Inc., 50 Williams Dr., Ramsey, NJ 07446
65–456	Tetracycline HCl capsules, USP	do.
95–736	Hygromycin B Type A medicated article	Mountaire Feeds, Inc.
98–895	Starbar GX–118 Topical (phosmet)(prolate)	Wellmark International, 1000 Tower Lane, Bensenville, IL 60106, formerly Sandoz Agro, Inc., 1300 East Touhy Ave., Des Plaines, IL 60018
137–138	Pyrantel tartrate Type A medicated article	Mountaire Feeds, Inc.
139–239	Banminth (pyrantel tartrate) Type A medicated article	Growmark, Inc., 950 North Meridian St., Indianapolis, IN 46204–3909, formerly at 1701 Towanda Ave., Bloomington, IL 61701

The sponsors are requesting withdrawal of approval of the NADA's because the products approved under the NADA's are no longer made or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA's 38–247, 44–013, 65–273, 65–456, 95–736, 98–895, 137–138, and 139–239, and all supplements and amendments thereto is hereby withdrawn, effective February 12, 1998.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending 21 CFR 510.600, 520.390b, 520.2345a, 524.1742, 558.274, 558.485, and 558.625 to reflect the withdrawal of approval of these NADA's.

Dated: January 8, 1998.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 98–2408 Filed 1–30–98; 8:45 am]

BILLING CODE 4160–01–F